BD Strengthens Leadership with New Board Appointments of Robert Huffines and Jacqueline Wright

BD Expands Board with Strategic Appointments

BD (Becton, Dickinson and Company), a leading global medical technology enterprise, has announced the strategic appointments of Robert 'Robbie' Huffines and Jacqueline 'Jacky' Wright to its Board of Directors, effective December 1, 2025. This move aims to bolster the company's governance and to align with its ambitious goals in healthcare innovation, digital transformation, and patient care improvement.

Expertise and Vision

Tom Polen, Chairman, CEO, and President of BD, emphasized that the addition of Huffines and Wright would inject valuable expertise into the board, specifically in the areas of healthcare technology, digital transformation, artificial intelligence, financial services, and capital markets. Their extensive backgrounds position them well to drive BD's strategy and enhance shareholder value while positively impacting patient care and health systems globally.

Robert Huffines: A Wealth of Financial Knowledge

Robert Huffines brings over 30 years of experience in advising healthcare firms on strategic planning, mergers, acquisitions, and financing to his new role on BD's board. A former global chairman of investment banking at J.P. Morgan Chase & Co., Huffines played a pivotal role in shaping financial strategies for healthcare entities. His leadership at J.P. Morgan included co-heading the global healthcare investment bank and functioning as a senior advisor on numerous high-profile transactions.

Resident of New Jersey, Huffines completed his bachelor's degree in English and economics at the University of North Carolina, followed by an MBA from the University of Virginia's Darden School of Business. He currently serves on the board of Insulet Corporation and is active in several non-profit organizations focusing on children's mental health.

Jacqueline Wright: A Leader in Digital Transformation

Jacqueline Wright complements Huffines’ financial acumen with her over 30 years of expertise in technology and digital strategy. Previously, she held the position of first chief technology and platform officer at McKinsey & Company, leading the firm’s technology portfolio and strategic initiatives. Her past roles at Microsoft Corporation, where she was a chief digital officer, and her work with the UK’s HM Revenue and Customs during a transformational period, underscore her proficiency in steering organizations through change.

Her educational credentials include a bachelor's degree in Computer Information Systems and Accounting from Bernard M. Baruch College, in addition to several honorary doctorates recognizing her contributions to technology and society.

BD: Driving Healthcare Forward

As one of the largest medical technology companies worldwide, BD is involved in advancing health by innovating medical research, diagnostics, and care delivery. The company recognizes the critical role it plays in healthcare and is determined to continue delivering high-quality products and solutions that enable healthcare professionals and laboratories to meet the demands of modern medicine.

With 70,000 employees worldwide, BD is committed to enhancing the clinical process and improving patient care outcomes. The addition of Huffines and Wright to the board underscores BD’s dedication to maintaining a cutting-edge focus in medical technology while fostering an environment that prioritizes governance and sustainable practices.

As the company progresses into its next phase of growth, the insights and leadership that Huffines and Wright bring will be essential to navigating the complexities of a rapidly-evolving healthcare landscape. BD remains committed to its mission: to improve lives through a relentless pursuit of innovation in healthcare delivery and medical solutions.

For more on BD's initiatives and leadership, visit their official website or connect on social media platforms.